Invizix Named Finalist in ADA 2026 Innovation Challenge

Key Takeaways

• Invizix said it was named an ADA Innovation Challenge finalist and invited to present at Scientific Sessions.
• The company describes its platform as a sleep-time bioelectronic therapy intended to work in the background of daily life, including at home during sleep.
• The release also notes a rebrand from Geminii Health, a Cell Metabolism publication, and an NIH Director's New Innovator Award.

Invizix, formerly Geminii Health, said it was selected as a finalist in the American Diabetes Association's 2026 Innovation Challenge. The company also said it was invited to present on the main stage at the ADA's 86th Scientific Sessions in New Orleans on June 6, 2026. A June 2 company press release from Chicago presented the development as a meeting milestone and public presentation opportunity. The invitation places the company before a professional diabetes audience on the meeting's main stage. The update centered on conference participation rather than new study results or detailed clinical validation.

According to Invizix, it is a clinical-stage bioelectronic medicine company developing sleep-time therapies for diabetes and other metabolism-driven diseases. Company materials describe the platform as a sleep-time bioelectronic therapy for age-related metabolism-driven diseases. It says electromagnetic fields are used to control glucose metabolism, while continuous monitoring, adherence tracking, and AI analytics support treatment personalization. The company adds that the system is meant to run in the background of daily life, including at home during sleep, rather than requiring active routine disruption. The combined therapy and monitoring approach is described as a personalized program for chronic metabolic conditions. In that description, the platform's intended role is ongoing metabolic management in a home setting.

The challenge is described as highlighting emerging companies that address longstanding problems in diabetes care. Finalists are said to be chosen for technology with potential to improve outcomes for people with diabetes, their families, and clinicians. The event is framed as a showcase for emerging approaches in diabetes care. The finalist designation reflects ADA recognition of the platform's potential rather than clinical validation of benefit. Invizix also says the company is led by Calvin Carter, PhD, and Sunny Huang, MD, PhD. In that context, the main development is a finalist presentation slot on a prominent conference stage.

The company says it recently rebranded from Geminii Health to Invizix as it develops what it characterizes as unobtrusive, non-drug therapies. It links that identity change to a platform built around invisible electromagnetic signals and background use during sleep at home. Invizix cites underlying science first published in Cell Metabolism and recognition through an NIH Director's New Innovator Award. Those references function as earlier milestones in the company's timeline rather than current evidence. The company also included forward-looking language about research and development plans, while noting risks and uncertainties. No clinical outcomes or comparative trial data were provided, so the update remains focused on platform development and a presentation opportunity rather than patient benefit.